Fate Therapeutics gives Q3 2026 update on lupus CAR T program and FT839 trial sites
Fate said Phase 1 data presented at ASN Kidney Week showed full renal response in the bendamustine cohort informing its RECLAIM-LN Phase 2 study, while FT839 sites begin activating.
FDA, SEC filing (3)